We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toGlobal-Rare-Disease-Town-Hall

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.


Global Rare Disease Town Hall

    Session Chair(s)
      James E. Valentine, JD, MHS

      James E. Valentine, JD, MHS

      • Attorney
      • Hyman, Phelps & McNamara, PC, United States
    Rare disease drug development is exploding and, in light of both old and new incentives programs to encourage drug development, the challenges of bringing these products to market continue to persist. Exploring the scientific and regulatory issues with experts to provide insights from those with the most experience in both successful and failed rare disease drug proposals.This forum will address the unique regulatory complexities and challenges specific to orphan drug development. It will provide key information about programs available to expedite the development of orphan products and will include audience Q&A.
    Learning Objective : Identify unique regulatory complexities and challenges specific to orphan drug development; Describe FDA programs available to expedite the development of orphan products; Recognize FDA requirements related to orphan drug regulation under 21st Century Cures and PDUFA VI.
    Speaker(s)
      Kristina  Larsson, MS

      EMA Perspective

      Kristina Larsson, MS

      • Head of Office for Orphan Medicines
      • European Medicines Agency (EMA), European Union, United Kingdom
      Ilan  Irony, MD

      Perspectives on Rare Diseases and Gene Therapies

      Ilan Irony, MD

      • Deputy Director / DCEPT/ OTAT/ CBER/ FDA
      • FDA, United States
      Lucas  Kempf, MD

      FDA Perspective

      Lucas Kempf, MD

      • Acting Associate Director, Rare Diseases Program, OND, CDER
      • FDA, United States